The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125275481 12527548 1 I 20151015 20160624 20160705 20160705 EXP US-ROCHE-1783222 ROCHE 31.95 YR F Y 66.20000 KG 20160705 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125275481 12527548 1 PS CELLCEPT MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE 1 Oral U 50722 2000 MG QD
125275481 12527548 2 SS CELLCEPT MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE 1 Oral U 50722 1500 MG BID
125275481 12527548 3 SS CELLCEPT MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE 1 Oral U 50722 1000 MG BID
125275481 12527548 4 SS BERAPROST SODIUM BERAPROST SODIUM 1 Unknown U 0 30 UG QD
125275481 12527548 5 SS BERAPROST SODIUM BERAPROST SODIUM 1 Unknown U 0 QID
125275481 12527548 6 SS TYVASO TREPROSTINIL 1 Intravenous (not otherwise specified) INHALATIONAL GAS 0.6 MG/ML 18-72 MCG Y 2100687 0 18 UG QID
125275481 12527548 7 SS TYVASO TREPROSTINIL 1 Intravenous (not otherwise specified) INHALATIONAL Y 2100687 0 288 UG
125275481 12527548 8 C ADCIRCA TADALAFIL 1 Oral 0 40 MG QD
125275481 12527548 9 C LETAIRIS AMBRISENTAN 1 Oral 0 10 MG QD
125275481 12527548 10 C NORVASC AMLODIPINE BESYLATE 1 Oral 0 10 MG QD
125275481 12527548 11 C PLAQUENIL HYDROXYCHLOROQUINE SULFATE 1 Oral 0 400 MG QD
125275481 12527548 12 C XARELTO RIVAROXABAN 1 Oral 0 20 MG QD
125275481 12527548 13 C CLARITIN LORATADINE 1 0
125275481 12527548 14 C ZANTAC RANITIDINE HYDROCHLORIDE 1 0
125275481 12527548 15 C TRAMADOL. TRAMADOL 1 Unknown AS NEEDED 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125275481 12527548 1 Systemic lupus erythematosus
125275481 12527548 4 Pulmonary arterial hypertension
125275481 12527548 6 Hypertension
125275481 12527548 8 Pulmonary arterial hypertension
125275481 12527548 9 Pulmonary arterial hypertension
125275481 12527548 10 Pulmonary arterial hypertension
125275481 12527548 11 Systemic lupus erythematosus
125275481 12527548 12 Pulmonary embolism
125275481 12527548 13 Hypersensitivity
125275481 12527548 14 Infusion site pain

Outcome of event

Event ID CASEID OUTC COD
125275481 12527548 HO
125275481 12527548 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125275481 12527548 Bacterial vaginosis
125275481 12527548 Neutropenia
125275481 12527548 Pulmonary function test decreased
125275481 12527548 Pulmonary hypertension
125275481 12527548 Supraventricular tachycardia

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125275481 12527548 1 20110608 0
125275481 12527548 5 20151015 0
125275481 12527548 6 20150326 0
125275481 12527548 7 20151026 0
125275481 12527548 8 20110501 0
125275481 12527548 9 20110910 0